142 related articles for article (PubMed ID: 38836983)
1. Pan-Cancer Analysis and Experimental Validation of CEND1 as a Prognostic and Immune Infiltration-Associated Biomarker for Gliomas.
Ma J; Lang B; Wang L; Zhou Y; Fu C; Tian C; Xue L
Mol Biotechnol; 2024 Jun; ():. PubMed ID: 38836983
[TBL] [Abstract][Full Text] [Related]
2. FAIM2 is a potential pan-cancer biomarker for prognosis and immune infiltration.
Cai J; Ye Z; Hu Y; Wang Y; Ye L; Gao L; Sun Q; Tong S; Sun Z; Yang J; Chen Q
Front Oncol; 2022; 12():998336. PubMed ID: 36185230
[TBL] [Abstract][Full Text] [Related]
3. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
[No Abstract] [Full Text] [Related]
4. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
5. Down-Regulation of CEND1 Expression Contributes to The Progression and Temozolomide Resistance of Glioma.
Houjun Z; Peng B
Cell J; 2023 Apr; 25(4):264-272. PubMed ID: 37210647
[TBL] [Abstract][Full Text] [Related]
6. Pan-cancer analysis of the disulfidptosis-related gene
Zong Y; Zhu A; Liu P; Fu P; Li Y; Chen S; Gao X
Heliyon; 2024 Jun; 10(11):e31875. PubMed ID: 38845861
[TBL] [Abstract][Full Text] [Related]
7. A pan-cancer characterization of immune-related NFIL3 identifies potential predictive biomarker.
Fei Q; Zhang X; Wang S; Shu G; Yin G
J Cancer; 2024; 15(5):1271-1286. PubMed ID: 38356719
[No Abstract] [Full Text] [Related]
8. Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy.
Jia Y; Guo B; Zhang W; Wang F; Zhang Y; Zhang Q; Li E
Front Oncol; 2023; 13():1110207. PubMed ID: 37427102
[TBL] [Abstract][Full Text] [Related]
9. Integrated pan-cancer analysis and experimental verification of the roles of tropomyosin 4 in gastric cancer.
Guo Q; Zhao L; Yan N; Li Y; Guo C; Dang S; Shen X; Han J; Luo Y
Front Immunol; 2023; 14():1148056. PubMed ID: 36993958
[TBL] [Abstract][Full Text] [Related]
10. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
11. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
Front Oncol; 2022; 12():927988. PubMed ID: 35756681
[TBL] [Abstract][Full Text] [Related]
12. Identifies microtubule-binding protein
Wang W; Zhang J; Wang Y; Xu Y; Zhang S
Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
[TBL] [Abstract][Full Text] [Related]
13. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of the prognostic and immunological signature of eight Tripartitemotif (TRIM) family molecules in human gliomas.
Lu J; Liang K; Zou R; Peng Y; Wang H; Huang R; Zeng Z; Feng Z; Fan Y; Zhang S; Ji Y; Pang X; Wang Y; Zhang H; Wang Z
Aging (Albany NY); 2023 Jun; 15(12):5798-5825. PubMed ID: 37367937
[TBL] [Abstract][Full Text] [Related]
15. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
[TBL] [Abstract][Full Text] [Related]
16. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
[TBL] [Abstract][Full Text] [Related]
17. A systematic analysis of
Jiang Y; Wang X; Li L; He J; Jin Q; Long D; Liu C; Zhou W; Liu K
Front Genet; 2022; 13():926943. PubMed ID: 35991552
[No Abstract] [Full Text] [Related]
18. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
20. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]